Beijing Med Pharm To Exclusively Market Novartis’ Enablex In China

SHANGHAI - Beijing Med-Pharm (BMP) entered into an exclusive licensing agreement Nov. 26 with Novartis subsidiary Shanghai Novartis Trading Limited, for its bladder treatment drug Enablex (darifenacin) in China